EUVIMEDEUVIMED entdecken
Übersichtsarbeit

CRISPR/Cas9 Genome Editing in Oncology: Mechanisms, Therapeutic Platforms and Translational Challenges

Anh-Duy Hoang Nguyen iD, Minh Trong Quang

Molecular Biotechnology · 2026

DOI: 10.1007/s12033-025-01533-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Biotechnology, 2026. Verfasst von Anh-Duy Hoang Nguyen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology - Parasitology, School of Pharmacy, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Neoplasms, Gene Editing. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 213 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The CRISPR/Cas9 genome editing technology has had a significant impact on cancer research and therapeutic development, providing unprecedented precision in manipulating cancer-associated genes. Although this review focuses on Cas9, we situate it within the broader CRISPR landscape that includes DNA-targeting effectors (Cas9/Cas12), RNA-targeting systems such as Cas13, and type III systems with dual DNA and RNA activity, modalities that expand both experimental and therapeutic possibilities. This comprehensive review examines the current applications of CRISPR/Cas9 in oncology, including its mechanisms and the challenges associated with its clinical translation. Knockout, interference, and activation CRISPR screening platforms have transformed functional genomics by systematically interrogating gene function, identifying therapeutic vulnerabilities, and clarifying resistance mechanisms across diverse cancer phenotypes. This technology has also reshaped cancer modeling, enabling precise recapitulation of disease-relevant mutations from engineered cell lines to patient-derived xenografts that capture tumor heterogeneity and microenvironmental interactions. Notably, the integration of CRISPR/Cas9 with CAR-T therapy has enabled multiplex editing to eliminate alloreactivity, overcome checkpoint-mediated exhaustion, and engineer universal CAR-T cells. Emerging in vivo strategies that directly generate or reprogram CAR-T cells in patients via targeted viral and nonviral delivery underscore accelerating translational momentum. However, significant challenges, including off-target mutagenesis, delivery barriers, p53-mediated selective pressure favoring potentially oncogenic populations, and Cas9 immunogenicity, continue to hinder clinical translation. These limitations necessitate high-fidelity nucleases, optimized guide designs, and improved delivery systems. The future of CRISPR/Cas9 in cancer therapy will depend on technological innovation, comprehensive safety frameworks, and rigorous clinical evaluation as next-generation editing modalities advance toward transformative precision oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CRISPR-Cas SystemsNeoplasmsGene EditingHumansAnimalsGenetic TherapyTranslational Research, Biomedical

Stichwörter der Autor:innen

CAR-T cellsCRISPR screeningCRISPR/Cas9Cancer therapyGene therapyGenome editing

Autor:innen und Institutionen

  • Department of Microbiology - Parasitology, School of Pharmacy, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.
  • Department of Microbiology - Parasitology, School of Pharmacy, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam. qtminh@ump.edu.vn.

ORCID-Profile: Anh-Duy Hoang Nguyen

Zitieren

APA

Nguyen, A. H., & Quang, M. T. (2026). CRISPR/Cas9 Genome Editing in Oncology: Mechanisms, Therapeutic Platforms and Translational Challenges. Molecular Biotechnology. https://doi.org/10.1007/s12033-025-01533-2

Vancouver

Nguyen AH, Quang MT. CRISPR/Cas9 Genome Editing in Oncology: Mechanisms, Therapeutic Platforms and Translational Challenges. Molecular Biotechnology. 2026. doi:10.1007/s12033-025-01533-2

BibTeX
@article{Nguyen2026,
  author = {Nguyen, Anh-Duy Hoang and Quang, Minh Trong},
  title = {CRISPR/Cas9 Genome Editing in Oncology: Mechanisms, Therapeutic Platforms and Translational Challenges},
  journal = {Molecular Biotechnology},
  year = {2026},
  doi = {10.1007/s12033-025-01533-2}
}
Kostenlos starten →